1445 related articles for article (PubMed ID: 35960235)
1. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
2. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
[TBL] [Abstract][Full Text] [Related]
3. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study.
Dinç HÖ; Demirci M; Özdemir YE; Sirekbasan S; Aktaş AN; Karaali R; Tuyji Tok Y; Özbey D; Akçin R; Gareayaghi N; Kuşkucu MA; Midilli K; Aygün G; Sarıbaş S; Kocazeybek B
Balkan Med J; 2022 May; 39(3):172-177. PubMed ID: 35378574
[TBL] [Abstract][Full Text] [Related]
5. Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses.
Glans H; Gredmark-Russ S; Olausson M; Falck-Jones S; Varnaite R; Christ W; Maleki KT; Karlberg ML; Broddesson S; Falck-Jones R; Bell M; Johansson N; Färnert A; Smed-Sörensen A; Klingström J; Bråve A
BMC Infect Dis; 2021 May; 21(1):494. PubMed ID: 34044758
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
7. The kinetics of viral load and antibodies to SARS-CoV-2.
Sun J; Tang X; Bai R; Liang C; Zeng L; Lin H; Yuan R; Zhou P; Huang X; Xiong Q; Peng J; Cui F; Ke B; Su J; Liu Z; Lu J; Tian J; Sun R; Ke C
Clin Microbiol Infect; 2020 Dec; 26(12):1690.e1-1690.e4. PubMed ID: 32898715
[TBL] [Abstract][Full Text] [Related]
8. A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A; Cosma C; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Galla L; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Jun; 60(7):1110-1115. PubMed ID: 35473824
[TBL] [Abstract][Full Text] [Related]
9. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
10. Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination.
Takahashi T; Ai T; Saito K; Nojiri S; Takahashi M; Igawa G; Yamamoto T; Khasawneh A; Paran FJ; Takei S; Horiuchi Y; Kanno T; Tobiume M; Hiki M; Wakita M; Miida T; Okuzawa A; Suzuki T; Takahashi K; Naito T; Tabe Y
PLoS One; 2023; 18(9):e0291670. PubMed ID: 37725623
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
[TBL] [Abstract][Full Text] [Related]
12. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections.
Wendel S; Fontão-Wendel R; Fachini R; Candelaria G; Scuracchio P; Achkar R; Brito M; Reis LF; Camargo A; Amano M; Machado R; Araujo D; Soares C; Durigon E
Transfusion; 2021 May; 61(5):1447-1460. PubMed ID: 33604884
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2.
Watanabe Y; Matsuba I; Watanabe K; Kunishima T; Takechi Y; Takuma T; Araki Y; Hirotsu N; Sakai H; Oikawa R; Danno H; Fukuda M; Futagami S; Wada K; Yamamoto H; Itoh F; Oda I; Hatori Y; Degawa H
J Clin Lab Anal; 2022 Jul; 36(7):e24545. PubMed ID: 35678628
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
15. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
[TBL] [Abstract][Full Text] [Related]
16. Detection of IgM, IgG, IgA and neutralizing antibody responses to SARS-CoV-2 infection and mRNA vaccination.
Fleischmann CJ; Bulman CA; Yun C; Lynch KL; Wu AHB; Whitman JD
J Med Microbiol; 2023 Jan; 72(1):. PubMed ID: 36748419
[No Abstract] [Full Text] [Related]
17. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
